前列腺特异性抗原相关变数与前列腺癌Gleason评分及临床分期的关系

目的:探讨前列腺特异性抗原(PSA)相关变数与前列腺癌病理分级及临床分期的关系。方法:回顾性分析125例经穿刺活检病理证实为前列腺癌患者的临床资料,采用Spearman相关分析探讨游离PSA(FPSA)、FPSA比率(F/TPSA)、PSA密度(PSAD)与Gleason评分及临床分期的关系。结果:FPSA与前列腺癌Gleason评分呈正相关(rS=0.499,P<0.001),与临床分期呈负相关(rS=-0.300,P<0.001);PSAD与前列腺癌Gleason评分呈正相关(rS=0.616,P<0.001),与临床分期无相关性(rS=-0.128,P=0.155);F/TPSA与前列腺癌Gleason评分呈弱相关(rS=0.182,P=0.042),与临床分期呈负相关(rS=-0.417,P<0.001)。结论:FPSA可作为前列腺癌病理分级和临床分期的参考指标;而PSAD可作为前列腺癌病理分级的参考指标,F/TPSA可作为前列腺癌临床分期的参考指标。

Relationship between prostate specific antigen related variables and Gleason score and clinical stage of prostate cancer

Aim:To explore the relationship between prostate specific antigen related variables and Gleason score and clinical stage in patients with prostate cancer.Methods:The clinical data from 125 cases of prostate cancer diagnosed by biopsies were collected,and the correlation of FPSA,F /TPSA and PSAD with Gleason score and clinical stagewas analyzed.Results:FPSA was positively correlated with Gleason score(rS = 0.499,P < 0.001),but negatively correlated with clinical stage(rS =-0.300,P < 0.001) for prostate cancer patients;PSAD was also positively correlated with Gleason score(rS = 0.616,P < 0.001),but not correlated with clinical stage(rS =-0.128,P = 0.155) for prostate cancer patients;F /TPSA was negatively correlated with clinical stage(rS =-0.417,P < 0.001),but weakly correlated with Gleason score(rS = 0.182,P = 0.042) for prostate cancer patients.Conclusion:FPSA could be used as a reference index in pathological grading and clinical staging for prostate cancer patients;PSAD could be used as a reference index in pathological grading and F /TPSA could be used as a reference index in clinical staging for prostate cancer patients.